BRISTOL MYERS SQUIBB CO (BMY) バランスシート

時価総額
$1193.8億
PER
16.9倍
研究開発から製造・販売まで手掛けるグローバルバイオ医薬品の最大手。がん、免疫、心血管、神経領域の革新的医薬品や抗PD-1などの免疫療法を展開。2024年にKaruna、RayzeBioを買収、ミラティを約48億ドルで買収。米国中心に製造拠点約130サイト、従業員約34,100人で43カ国に展開。
2010/122011/122012/122013/122014/122015/122016/122017/122018/122019/122020/122021/122022/122023/122024/122025/12
現金同等物5,0335,7761,6563,5865,5712,3854,2375,4216,91112,82014,97314,3169,32511,51910,34710,218
現金 + 有価証券5,0335,7761,6563,5865,5712,3854,2375,4216,91112,82014,97314,3169,32511,51910,34710,218
商品及び製品1,2041,3841,6571,4981,5601,2211,2411,1661,1954,2932,0742,0952,3392,6622,5572,690
流動資産合計13,27315,3189,52118,91614,60810,41513,70414,85417,16029,35430,19233,26227,27331,77029,78029,390
有形固定資産4,6644,5215,3334,5794,4174,4124,9805,0015,0276,2525,8866,0496,2556,6467,1367,543
投資有価証券2,6812,9093,5233,7474,4084,6602,7192,4801,775767433--364320396
総資産31,07632,97035,89738,59233,74931,74833,70733,55134,986129,944118,481109,31496,82095,15992,60390,038
買掛金1,9832,6032,2022,5592,4871,5651,6642,2481,8922,4452,7132,9493,0403,2593,6023,575
一年内返済予定の長期借入金---------2,7632,0004,7643,8972,8731,8281,977
流動負債合計6,7397,7808,27912,4408,4618,0178,8419,56310,65418,30419,08021,86821,89022,26223,77423,417
長期借入金5,3285,3766,5687,9817,2426,5505,7166,9755,64643,38748,33639,60535,05636,65347,60342,850
総負債15,43817,10322,25923,35618,76617,32417,36021,70420,85978,24680,59973,30865,70265,67476,21571,533
利益剰余金31,63633,06932,73332,95232,54131,61333,51331,16034,06534,47421,28123,82025,50328,76614,91216,896
株主資本15,71315,95613,63815,23614,98314,42416,34711,84714,12751,69837,88236,00631,11829,48516,38818,506
AIチャット